The significance of diagnosing associated clonal mast cell diseases in patients with venom-induced anaphylaxis and the role of bone marrow investigation

Clinical and Translational Allergy

Gunnar Nilsson²  Hans Hägglund²  Birgitta Sander²  Barbro Dahlén²  Theo Gülen¹ 

[1] Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden;Mastocytosis Center Karolinska, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

关键词: Serum tryptase;    Mast cell clonality;    Mastocytosis;    Hymenoptera sting;    Anaphylaxis;   

Others  :  794290
DOI  :  10.1186/2045-7022-3-22

 received in 2013-05-02, accepted in 2013-06-16,  发布年份 2013

【 摘 要 】

Hymenoptera venom allergy (HVA) represents a particular risk for exceptionally severe anaphylactic sting reactions in patients with clonal mast cell disorders (CMD). Nevertheless, conventional investigations are not sufficient to do accurate risk assessments. Increased levels of baseline serum tryptase (sBT) (>11.4 μg/L) is highly associated with severe anaphylactic reactions and with a possible underlying CMD. The measurement of baseline serum tryptase, thus, has opened the possibility to screen for CMD. In the present study, we sought to investigate whether bone marrow evaluation provides more accurate diagnosis in patients with HVA.

Three patients of the same sex and similar age with HVA were enrolled in this clinical study. The patients underwent comprehensive allergy work-up including skin prick testing, measurements of serum total IgE concentrations and baseline serum tryptase. Bone-marrow biopsies were also performed in all three patients to assess underlying CMD.

We evaluated characteristics of the bone marrow mast cells by pathology, flow cytometry and detection of D816V mutation by using current WHO-criteria, which led to changes in the final diagnosis compared to the assessments done by classical allergy work-up and measurements of sBT. Three distinct diagnostic outcomes including systemic mastocytosis, monoclonal mast cell activation syndrome and non-clonal HVA were revealed.

We conclude that a bone marrow investigation is required for the correct diagnosis of hymenoptera venom-induced anaphylactic reactions in patients with elevated baseline tryptase levels (>11.4 μg/L), and this has important implications for management strategies.

【 授权许可】

   
2013 Gülen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Dubois AE: Mastocytosis and hymenoptera allergy. Curr Opin Allergy Clin Immunol 2004, 4(4):291-295.
• [2]Ruëff F, Placzek M, Przybilla B: Mastocytosis and hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006, 6(4):284-288.
• [3]Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, Castellani L, Bonetto C, Frattini F, Dama A, Martinelli G, Chilosi M, Senna G, Pizzolo G, Zanotti R: Clonal mast cell disorders in patients with systemic reactions to hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009, 123(3):680-686.
• [4]Oude Elberink JNG, de Monchy JGR, Kors JW, van Doormaal JJ, Dubois AEJ: Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997, 99(1):153-154.
• [5]Reimers A, Müller U: Fatal outcome of a Vespula sting in a patient with mastocytosis after specific immunotherapy with honey bee venom. Allergy Clin Immunol Int J WAO Org 2005, 17(Suppl 1):S69-S70.
• [6]Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van Doormaal J, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD: Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37(6):435-453.
• [7]Akin C, Scott LM, Kocabas CN, Kushnir-Sukhov N, Brittain E, Noel P, Metcalfe DD: Demonstration of an aberrant mast cell population with clonal markers in a subset of patients with ‘idiopathic’ anaphylaxis. Blood 2007, 110(7):2331-2333.
• [8]Sonneck K, Florian S, Mullauer L, Wimazal F, Födinger M, Sperr WR, Valent P: Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2007, 142(2):158-164.
• [9]Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A: KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders. A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
• [10]Bilo MB, Rueff F, Mosbech H, Bonifazi F, Oude Elberink JN: Diagnosis of hymenoptera venom allergy. Allergy 2005, 60(11):1339-1349.
• [11]Johansson SGO, Nopp A, van Hage M, Olofsson N, Lundahl J, Wehlin L, Söderström L, Stiller V, Oman H: Passive IgE-sensitization by blood transfusion. Allergy 2005, 60(9):1192-1199.
• [12]Georgitis JW, Reisman RE: Venom skin tests in insect-allergic and insect-nonallergic populations. J Allergy Clin Immunol 1985, 76(6):803-807.
• [13]Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW: Second symposium on the definition and management of anaphylaxis: summary report–Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117(2):391-397.
• [14]Horny HP, Valent P: Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001, 25(7):543-551.
• [15]Escribano L, Orfao A, Diaz-Agustin B, Villarrubia J, Cerveró C, López A, Marcos MA, Bellas C, Fernández-Cañadas S, Cuevas M, Sánchez A, Velasco JL, Navarro JL, Miguel JF: Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998, 91(8):2731-2736.
• [16]Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bültmann B: One-step detection of c-kit point mutations using PNA-mediated PCR-clamping and hybridization probes. Am J Pathol 2003, 162(3):737-746.
• [17]Golden DBK, Kagey-Sobotka A, Hamilton RG, Norman PS, Lichtenstein LM: Insect allergy with negative venom skin tests. J Allergy Clin Immunol 2001, 107(5):897-901.
• [18]Kranke B, Sturm G, Aberer W: Negative venom skin test results and mastocytosis. J Allergy Clin Immunol 2004, 113(1):180-181.
• [19]Bonadonna P, Zanotti R, Melioli G, Antonini F, Romano I, Lenzi L, Caruso B, Passalacqua G: The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. Allergy 2012, 67(7):962-965.
• [20]Ludolph-Hauser D, Ruëff F, Fries C, Schöpf P, Przybilla B: Constitutionally raised serum concentrations of mast-cell tryptase and severe anaphylactic reactions to hymenoptera stings. Lancet 2001, 357(9253):361-362.
• [21]Haeberli G, Bronnimann M, Hunziker T, Muller U: Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003, 33(9):1216-1220.
• [22]Bonadonna P, Zanotti R, Muller U: Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010, 10(4):347-353.
• [23]Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, Mateo MB, Alonso Díaz de Durana MD, DelaHoz B, del Pozo Gil MD, Caballero T, Rosado A, Sánchez Matas I, Teodósio C, Jara-Acevedo M, Mollejo M, García-Montero A, Orfao A, Escribano L: Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010, 125(6):1269-1278.